Introduction：Basic information about CAS 113775-47-6|Dexmedetomidine, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Dexmedetomidine |
|---|
| CAS Number | 113775-47-6 | Molecular Weight | 200.28000 |
|---|
| Density | 1.053g/cm3 | Boiling Point | 381.9ºC at 760mmHg |
|---|
| Molecular Formula | C13H16N2 | Melting Point | 146-149°C |
|---|
| MSDS | / | Flash Point | 191.3ºC |
|---|
Names
| Name | dexmedetomidine |
|---|
| Synonym | More Synonyms |
|---|
Dexmedetomidine BiologicalActivity
| Description | Dexmedetomidine ((+)-Medetomidine) is a potent, selective and orally active agonist of α2-adrenoceptor, with a Ki of 1.08 nM. Dexmedetomidine shows 1620-fold selectivity against α1-adrenoceptor. Dexmedetomidine exhibits anxiolysis, sedation, and modest analgesia effects[1][2][3]. |
|---|
| Related Catalog | Signaling Pathways >>GPCR/G Protein >>Adrenergic ReceptorResearch Areas >>Neurological Disease |
|---|
| Target | α2-adrenergic receptor:1.08 nM (Ki) |
|---|
| In Vitro | Medetomidine has high selectivity for α2 adrenoceptors (Ki=1.08 nM) over α1 adrenoceptors (Ki=1750 nM) in rat brain membranes as measured by the displacement of [3H]clonidine[1]. Medetomidine (0.1-100 nM) inhibits the twitch response in field-stimulated mouse vas deferens, with a pD2 of 9.0[1]. |
|---|
| In Vivo | Medetomidine (10-100 μg/kg; i.v. at 5-min intervals) produces a dose-dependent pupillary dilatation in pentobarbitone-anaesthetized rats[1]. Animal Model: Female Sprague-Dawley rats (270-350 g)[1] Dosage: 1, 5, 10, 50, 100 mg/kg Administration: I.v. at 5-min intervals Result: Produced the pupil dilatation of 2.5 mm (approximately half of the maximum effect) at the cumulative dose of 4 μg/kg. |
|---|
| References | [1]. Virtanen R, et, al. Characterization of the selectivity, specificity and potency of medetomidine as an alpha 2-adrenoceptor agonist. Eur J Pharmacol. 1988 May 20;150(1-2):9-14. [2]. Gertler R, et, al. Dexmedetomidine: a novel sedative-analgesic agent. Proc (Bayl Univ Med Cent). 2001 Jan;14(1):13-21. [3]. Sajid B, et, al. A comparison of oral dexmedetomidine and oral midazolam as premedicants in children. J Anaesthesiol Clin Pharmacol. Jan-Mar 2019;35(1):36-40. |
|---|
Chemical & Physical Properties
| Density | 1.053g/cm3 |
|---|
| Boiling Point | 381.9ºC at 760mmHg |
|---|
| Melting Point | 146-149°C |
|---|
| Molecular Formula | C13H16N2 |
|---|
| Molecular Weight | 200.28000 |
|---|
| Flash Point | 191.3ºC |
|---|
| Exact Mass | 200.13100 |
|---|
| PSA | 28.68000 |
|---|
| LogP | 3.17830 |
|---|
| Vapour Pressure | 1.08E-05mmHg at 25°C |
|---|
| Index of Refraction | 1.569 |
|---|
| InChIKey | CUHVIMMYOGQXCV-NSHDSACASA-N |
|---|
| SMILES | Cc1cccc(C(C)c2cnc[nH]2)c1C |
|---|
| Storage condition | 2-8°C |
|---|
Safety Information
Customs
| HS Code | 2933290090 |
|---|
| Summary | 2933290090. other compounds containing an unfused imidazole ring (whether or not hydrogenated) in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
|---|
Synonyms
| Dexmedetomidine |
| 5-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole |
| Dexmedetomidina |
| (S)-medetomidine |
| Dexmedetomidinum |
| 1H-Imidazole,5-[(1S)-1-(2,3-dimethylphenyl)ethyl]- |
